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ABSTRACT Inadequate surgical margins represent a high
risk for adverse clinical outcome in breast-conserving
therapy (BCT) for early-stage breast cancer. The majority
of studies report positive resection margins in 20% to 40%
of the patients who underwent BCT. This may result in an
increased local recurrence (LR) rate or additional surgery
and, consequently, adverse affects on cosmesis, psycho-
logical distress, and health costs. In the literature, various
risk factors are reported to be associated with positive
margin status after lumpectomy, which may allow the
surgeon to distinguish those patients with a higher a priori
risk for re-excision. However, most risk factors are related
to tumor biology and patient characteristics, which cannot
be modiﬁed as such. Therefore, efforts to reduce the
number of positive margins should focus on optimizing the
surgical procedure itself, because the surgeon lacks real-
time intraoperative information on the presence of positive
resection margins during breast-conserving surgery. This
review presents the status of pre- and intraoperative
modalities currently used in BCT. Furthermore, innovative
intraoperative approaches, such as positron emission
tomography, radioguided occult lesion localization, and
near-infrared ﬂuorescence optical imaging, are addressed,
which have to prove their potential value in improving
surgical outcome and reducing the need for re-excision in
BCT.
Breast cancer is the most common form of cancer and
second leading cause of death in women in Europe and the
United States.
1,2 During the last 30 years, wide-spread
mammographic screening and technological developments
have led to a rapid increase in the diagnosis of small,
nonpalpable breast cancer.
3,4 Breast-conserving therapy
(BCT), consisting of lumpectomy and irradiation therapy,
has become the standard treatment for T1-T2 breast tumors
and is regarded generally sufﬁcient in appropriately
selected patients.
5,6
Large, randomized, clinical trials (RCTs) have reported
no signiﬁcant difference in disease-free and overall sur-
vival between BCT and traditional mastectomy.
7–9 BCT is
considered to be associated with a diminished psycholog-
ical burden compared with mastectomy, offers better
cosmetic results, and reduces wound infection risk.
10 The
most important disadvantage of BCT is the lifelong risk for
local recurrence (LR), in which case additional surgery is
necessary.
11 Large clinical trials have reported LR rates
between 6% and 16%.
12–14
Accurate localization is essential for adequate surgical
removal of breast tumors, in which an optimal balance
between good cosmetic results and preservation of resection
margins is the primary goal. Obtaining tumor-free surgical
margins decreases the incidence of LR of the primary
tumor.
11,15,16 However, previous studies have shown that
the number of patients exposed to BCT in whom tumor cells
were present at or near the cut edge of the surgical specimen
after resection of the primary tumor ranged from 5% to
82%, with the majority of studies indicating positive mar-
gins in 20% to 40% of patients.
10,17–21 To obtain tumor-free
margins, mutilating additional surgical procedures have to
be performed.
11,15,16
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applied as a boost to the tumor bed or, postoperatively, to
the biopsy scar.
22,23 Boost radiation, as an additive to
standard whole-breast radiation therapy, reduces the LR
rate; the absolute effect of radiation therapy is of greatest
beneﬁt to women with higher risk of LR (p\0.0001).
23–27
Adverse effects associated with boost radiation include
decreased cosmetic outcome, delayed wound healing,
27,30
and altered postoperative mammographic and ultrasono-
graphic ﬁndings at the original tumor site in case of
detection of recurrent disease.
28–30
BCT still has limitations in achieving an acceptable
therapeutic outcome.
10 This review paper outlines the
major challenges currently encountered intraoperatively
and demarcates risk factors for positive resection margins
and LR. In addition, current imaging modalities and future
directions in achieving the highest feasible percentage of
negative surgical margins in BCT are addressed.
CLINICAL IMPACT OF POSITIVE MARGINS
To assess strategies to decrease LR rates after BCT,
several RCTs were performed and revealed numerous and
varying risk factors that might be associated with LR
(Table 1). A large meta-analysis of 72 trials, containing
information on [42,000 patients, assessed that local sur-
gical control at 5 years showed a signiﬁcant improvement
in disease-free survival and overall mortality at 15 years
follow-up.
24
The inﬂuence of ‘‘close’’ margins, usually deﬁned as
tumor cells being present within[0 and B2 mm from the
cut edge, is still controversial.
4 Several studies reported
close margins to be a signiﬁcant risk for increased rates of
LR, as well as the apparent quantity of cancerous cells
approaching the cut edge.
31–34
In a recent trial conducted by Zavagno et al., 431
patients who underwent re-excision due to margin
involvement were evaluated from a total of 1,520 patients
who underwent BCT.
35 The authors found LR rates after
positive margins and close margins to be 51.8% and 34.1%,
respectively (p = 0.001). However, no correlation was
found between the distance of the tumor from the cut edge
(range: 0.08–3 mm) and LR rate.
35 These ﬁndings are
consistent with the results of most of the studies performed
on the correlation between margin width and LR rate, as
reviewed by Singletary.
4 Margin closeness is therefore
currently not seen as an indication for re-excision.
Zavagno et al. suggest that residual disease in close
margin involvement may be largely due to the existence of
multiple cancerous foci and not to margin closeness by
itself.
35 Breast tumors are shown to grow multifocally in
59%, of which 71% grow at a distance [2 cm from the
reference tumor.
36 Therefore, margin status as such may be
considered an important judgment factor in planning re-
excision, but cannot be seen as an indicator for the pres-
ence of residual tumor in the surrounding tissue.
35
Adequate perioperative imaging of cancerous foci may be
of great value to the surgeon.
Singletary reviewed 34 studies on margin status and LR,
in which a total of[15,000 patients were assessed.
4 In 30
of 34 reviewed studies, persistent microscopic inadequate
(R1) or macroscopic inadequate (R2) surgical margins
were highly signiﬁcant for LR compared with negative
margins (p = 0.0001), depicting the relevance of margin
status on the outcome of BCT. In a study by Jobsen et al. of
approximately 2,300 patients, the LR rate was found to
be related to positive margin status and young age.
37 The
authors found the 10-year LR-free survival rate for young
women (B40 years) with positive margins to be signiﬁ-
cantly lower compared with negative margins (34.6% vs.
84.4%, respectively; p = 0.008). The effect of positive
margin status for invasive carcinoma seems to be limited to
young women and is not only restricted to local control, but
also to distant metastasis and survival.
37
Because positive margin status is found to be an
important risk factor for LR, substantial efforts have been
made to understand the causes of the relatively high per-
centage of positive margins after BCT. A number of risk
factors for positive margin status have been identiﬁed over
the years (Table 2). Again, young age is reported to be a
strong risk factor for positive margin status.
20,37–41 Vrieling
et al. reported that the tumor was signiﬁcantly larger in
young patients (B40 years) compared with older
patients (p = 0.001).
38 Furthermore, re-excisions occurred
more often in younger patients (34–35% vs. 20–28%;
p = 0.001), which was probably related to a more frequent
incomplete excision at the ﬁrst attempt (24–26% vs.
14–21%; p = 0.001). Vicini et al. suggested that a lesser
extent of the excision, for cosmetic reasons, might be the
cause of less optimal margin resection in younger
patients.
34 When adequate negative margins were obtained,
no difference in LR was seen in different age groups.
34
Other reported risk factors for positive margin status are
large tumor size, multifocality, and lobular histological
type.
17,20,39–43 Furthermore, the number of positive lymph
nodes (N-status) is reported to be a risk factor.
44 However,
it should be noted that there is a strong variability in the
reported ﬁndings of these studies.
An explanation for the high rate of positive margins
reported in literature might be the restricted visibility of the
tumor and coexisting ductal carcinoma in situ (DCIS)
during surgery. To give an adequate perspective on the
problems surrounding the pre- and intraoperative visibility
of the tumor, the techniques currently used are summarized
in the following sections and judged on their merits.
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CANCER IN BCT
Clinical Aspects in Patient Selection
Approximately one third of all diagnosed breast cancers
is clinically occult. As a consequence, additional tech-
niques have to be used to localize the tumor adequately. By
current standards, the tumor is visualized with X-ray
mammography or ultrasonography before the surgical
procedure. However, during the lumpectomy procedure,
the surgeon relies mostly on palpation of the tumor.
45
Palpation of the tumor alone is considered inadequate for
optimal lumpectomy due to a few basic shortcomings:
difﬁculty detecting occult or multicentric disease and dif-
ﬁculty differentiating between malignant tissue and
ﬁbrosis. Furthermore, tumors in younger women are harder
to detect because of the ﬁrmer nature of the breast tissue.
42
Therefore, most institutions use additional intraoperative
techniques to evaluate surgical margins, which may assist
in obtaining margin negativity. Because none of these
techniques fully guarantee the detection of a negative
margins status, preoperative imaging is an absolute
necessity for adequate BCT.
Preoperative Mammography
Due to widespread mammographic screening programs,
radiographic X-ray mammography is currently the com-
mon way of detecting breast malignancy. Mammography
gives an accurate assessment of tumor size and borders. It
also provides information on the presence of multicen-
tricity, multifocality, and microcalciﬁcation, which is
considered to be a sign for the presence of DCIS.
46,47 In a
recent meta-analysis on the efﬁcacy of mammography for
the detection of tumors, sensitivity and speciﬁcity rates of
94% and 61% were found, respectively.
48 Although
mammography is an adequate technique for breast cancer
detection, it has a relatively high rate of nonspeciﬁc ﬁnd-
ings.
49 Furthermore, it does not give any functional
TABLE 2 Independent risk factors associated with positive margins
Study Year No. of
patients
Study
design
Rate
positive
margins
(%)
Deﬁnition
positive
margins
Analysis Risk factors for positive margin p value
Kurniawan
et al.
39
2008 1648 Retrospective 13.5 0 mm Multivariate Multifocal disease (vs. unifocal) \0.0001
Unicenter
c Tumor size C30 mm (vs.\30 mm) \0.0001
Microcalciﬁcations on mammogram
(vs. none)
0.001
Smitt et al.
149 2007 395 Retrospective 43.1 0 mm v
2 Excisional biopsy (vs. core/needle biopsy) \0.0001
Unicenter Presence of EIC (vs. absence) 0.002
Age B 45 yr (vs.[45 yr) 0.02
ER status negative (vs. positive) 0.02
Lobular histological type (vs. other) 0.02
Cabioglu
et al.
40a
2007 264 Retrospective 20 0 mm Multivariate Diagnosis by excisional biopsy (vs. other) \0.0001
Unicenter Multifocality (vs. unifocality) 0.020
Tumor size[20 mm (vs. B20 mm) 0.028
Aziz et al.
147 2006 1430 Retrospective 14.3 0 mm Multivariate Age\50 yr (vs. C50 yr) \0.0001
Unicenter
Dillon et al.
41b 2006 612 Retrospective 34 \5m m v
2 Absence of preoperative diagnosis (vs.
presence)
\0.001
Unicenter Presence of EIC (vs. absence) 0.002
Referred from screening (vs. symptomatic) 0.018
Lobular histological type (vs. other) 0.024
Large tumor size (vs. small) 0.04
Chagpar et al.
20 2004 2658 Prospective 12.4 0 mm Multivariate T3 tumor (vs. T1-T2) \0.001
Multicenter Lobular histological type (vs. ductal) 0.036
EIC extensive intraductal component, ER estrogen receptor
a Risk factors associated with close or positive margin
b Risk factors associated with compromised margin (deﬁned as tumor-free margin: C1 mm and\5 mm)
c Data were collected at one institute; surgical excision was performed at multiple institutions
2720 R. G. Pleijhuis et al.information nor does it provide any quantitative informa-
tion on tissue function or composition.
50
Because of the aforementioned shortcomings, ultrasound
was introduced as an addition to mammography for pre-
operative tumor assessment. Whereas radiography provides
information on tissue density and microcalciﬁcations,
ultrasound gives a more accurate image of tumor size and
growth pattern. Although both imaging modalities act
complementary, they fail to assess tumor size and growth
pattern in a substantial percentage of patients. Deurloo et al.
found an underestimation in tumor extent of 23% in patients
considered eligible for BCT, largely due to failure in
assessing diffuse and multinodular tumors.
51,52 Especially
patients of younger age present difﬁculties. An earlier study
found failure to meet malignancy criteria in 13% of patients
assessed preoperatively by ultrasound alone.
53
Preoperative Magnetic Resonance Imaging
Magnetic resonance imaging (MRI) is a highly sensitive
imaging technique, which is reported to be a substantial
improvement in detecting multinodular disease and
assessment of tumor spread compared with conventional
techniques.
54,55 MRI provides highly sensitive information
on ductal carcinoma in situ.
56 In a trial conducted in Bel-
gium, MRI detected intraductal extent in 34 out of 50 (68%)
patients who were reported to have an intraductal compo-
nent, compared with 48.5% in mammography and 34.2% in
ultrasound.
57 Furthermore, MRI has an accurate capability
to differentiate between malignant tissue and ﬁbrosis,
enabling assessment of breast tissue after irradiation or
chemotherapy for the presence of recurrent disease.
58 MRI
is equally accurate in distinguishing malignancies in
younger women with more extensive ﬁbroglandular tissue.
In a meta-analysis of 2,160 patients in 16 studies, Houssami
et al. showed that MRI detects additional disease in 16% of
patients with breast cancer, leading to conversion of local
excision to mastectomy in 1.1% (95% conﬁdence interval
(CI), 0.3–3.6) and to otherwise extended surgery in 5.5%
(95% CI, 3.1–9.5).
59 The authors reported a relatively high
false-positive ratio (true-positive to false-positive ratio of
1.91 (95% CI, 1.09–3.34)), for which further research on its
clinical value is necessary. Nevertheless, MRI has been
shown to have a profound clinical impact on selection of
patients for BCT and is currently regarded as the preferred
imaging modality for preoperative assessment and clinical
decision making.
It should be emphasized that several studies have shown
that MRI assessment before surgery fails to improve
postoperative margin status and subsequent LR, even
compared with conventional imaging modalities.
60,61 The
intraoperative limitation may be due to the limited provi-
sion of real-time margin assessment.
62
INTRAOPERATIVE TUMOR LOCALIZATION
Because of the limited intraoperative capabilities of the
current preoperative imaging techniques, more invasive
imaging and surgical guidance techniques have been
developed to assess the location of the tumor intraopera-
tively, which will be addressed in the next section.
Wire-Guided Localization
For more than 20 years, the standard technique for
intraoperative tumor localization of clinically occult
tumors has been wire-guided localization (WGL), in which
a wire is introduced in the tumor guided by ultrasound, X-
ray mammography, or MRI. After resection, the excised
lump can be evaluated mammographically for localization
of the tumor and microcalciﬁcations. However, the WGL
procedure has been criticized for the last 5 years.
Burkholder et al. recently analyzed the success rate of
WGL in a retrospective study of 511 patients and found
positive to close (\3 mm) margins in 21.3% of the
patients, of which 26.7% had to undergo re-excision.
63
Similar percentages were found by Schmidt-Ullrich et al.
64
Two recent studies reported that WGL resulted in positive
margins in up to 38% to 43% of the patients who under-
went BCT.
3,65
An important disadvantage of WGL is that the guide-
wire does not provide a clear three-dimensional perspective
on the various tumor edges and does not inﬂuence surgical
margins as such. Furthermore, the guidewire is prone to
move before or during surgery and may for this reason lead
to inadequate information on tumor localization. The WGL
procedure is time consuming and uncomfortable for the
patient, resulting in increased levels of stress and arousal.
66
Because WGL results in an unacceptable high rate of
positive margins, other techniques have been developed for
intraoperative tumor detection.
Intraoperative Ultrasound-Guided Resection
Current trends in BCT are moving toward the direction
of one combined diagnostic and therapeutic procedure, a
so-called ‘‘theragnostic’’ procedure, in which effective
visualization plays a more prominent role. One of these
theragnostic procedures is intraoperative ultrasound
(IOUS)-guided excision. In this technique, the patient is
examined with ultrasound (US) before and during surgery
to improve tumor assessment. After surgery, the excised
tissue is examined using US to assess margin status. In case
of positive or close margins, the patient’s cavity margins
are shaved to remove any residual disease.
67
Several studies investigating the use of IOUS in BCT
showed positive margin rates between 3% and 11%.
68–71
Surgical Margins in Breast-Conserving Therapy 2721Rahusen et al. compared IOUS to WGL in a prospective
study in 48 patients.
70 The authors reported that positive or
close margin status (B1 mm) was improved signiﬁcantly
using IOUS compared with WGL (11% vs. 45%, respec-
tively; p\0.007). However, Klimberg showed that only
half (50%) of the nonpalpable breast tumors can be visu-
alized by ultrasonography.
72 Another problem of IOUS is
the unreliability in detecting DCIS lesions, because ultra-
sonography is not suitable for the detection of
microcalciﬁcations.
73
Karni et al. reported on a radiofrequency-based intra-
operative margin assessment device (MarginProbe
TM,
Dune Medical Devices Ltd., Israel), which is able to detect
malignant tissue within the surgical specimen up to a depth
of 1 mm.
74 The MarginProbe
TM displays device readings
as ‘‘negative’’ or ‘‘positive’’ margin, the latter indicating
excision of additional breast tissue. Sensitivity and speci-
ﬁcity rates of the MarginProbe
TM were reported to be 71%
and 68%, respectively.
74 Recently, Allweis et al. showed
re-excision rates to be lower if the surgeon had a Mar-
ginProbe
TM at his disposal during breast-conserving
surgery compared with the control group, although not
statistically signiﬁcant (12.6% vs. 18.6%; p = 0.098).
75
However, this reduction in re-excision rate might, in part,
have been due to the excision of larger tissue volumes in
the device group compared with the control group
(107 cm
3 vs. 94 cm
3, respectively; p = 0.066).
Intraoperative Specimen Radiography
Another technique for evaluation of surgical margins is
intraoperative specimen radiography. After excision by the
surgeon, the specimen is evaluated by X-ray radiography.
If microcalciﬁcations occur close to the edges of the
specimen, the surgeon may decide to shave the associated
cavity edges to remove any residual malignant disease.
However, the use of radiographic X-ray mammography is
limited due to limitations in detecting small, noncalciﬁed
lesions and a high rate of nonspeciﬁc ﬁndings.
76 Lee and
Carter examined postexcision specimen radiographs of 125
patients and found a sensitivity, speciﬁcity, and overall
accuracy for detecting margin positivity of 49%, 77%, and
62%, respectively.
77 They concluded that intraoperative
specimen radiography could not be relied on solely but
presents a valuable addition to BCT.
Cryoprobe-Assisted Localization
Cryoprobe-assisted localization (CAL) is a technique of
particular value in small, nonpalpable tumors. This tech-
nique makes use of an ultrasound-guided cryoprobe, which
is inserted into the breast and freezes the tumor, thereby
turning the tumor into a small, palpable sphere that can be
more easily located and excised. Tafra et al. compared the
capability of CAL in achieving negative margins to con-
ventional WGL in a prospective trial in 310 patients.
78 No
signiﬁcant differences were found between the CAL and
WGL arms in positive surgical margin status (28% vs.
31%; p = 0.691) and re-excision rates (19% vs. 21%;
p = 0.764). However, it did reduce the amount of healthy
surrounding tissue excised and therefore improved cos-
metic outcome (p\0.001). Furthermore, excision time
and ease were signiﬁcantly improved using the CAL
method (p\0.001).
78
INTRAOPERATIVE PATHOLOGICAL
EXAMINATION
Frozen Section Analysis
Frozen section analysis (FSA) is a commonly applied
technique for intraoperative pathological margin assess-
ment in many oncologic procedures. The excised specimen
is frozen, sliced, and analyzed microscopically.
79 Because
of the relative ease and the wide experience gained, this
technique has been applied frequently to assess tumor
margins during lumpectomy. The procedure is performed
directly after the tumor has been excised. In case FSA
indicates residual disease, the wound can be reopened
immediately for additional surgical cavity shaving, thus
preventing a costly re-excision procedure at a later stage.
The FSA procedure takes an average of 30 minutes, which
adds signiﬁcantly to the operating time.
80
Reported sensitivity rates for detecting residual disease
ranged between 65% and 78%, whereas speciﬁcity rates
ranged between 98% and 100%.
40,81,82 The relatively high
variance in sensitivity might be explained by differences in
experience between pathologists.
Several studies retrospectively analyzed the inﬂuence of
FSA on BCT outcome and found that 24% to 27% of the
patients underwent additional tissue excision based on FSA,
whereas 5% to 9% required a second re-excision procedure
after deﬁnitive histopathological examination.
80,82,83 FSA
during BCT did not improve overall LR rates (3.8% and
1.2%, respectively).
80,83 Considering the costs of the FSA
procedure (the average Medicare charge for FSA is esti-
matedatUS$90),theselowre-excisionratesclearlyindicate
the beneﬁts of the procedure compared with permanent
pathological evaluation alone. Nevertheless, in evaluating
small tumors (diameter\10 mm) and presence of DCIS, the
technique is less reliable.
80,81 Other disadvantages of FSA
are the prolonged duration of operation time and the
requirement of arelatively large part of the specimen, which
compromises deﬁnitive evaluation by the pathologist for
histological aspects and tumor staging. In conclusion,
although FSA is a relatively safe and cost-effective
2722 R. G. Pleijhuis et al.procedure that reduces the rate of re-excisions signiﬁcantly,
its reliability for negative margin status is questionable due
to relatively high variance in diagnostic sensitivity.
Intraoperative Touch Preparation Cytology
Intraoperative touch preparation cytology (IOTPC) or
‘‘imprint cytology’’ is a promising alternative to FSA. The
technique is based on the histological characteristics of the
cell surface of malignant cells, which stick to glass sur-
faces, whereas benign mammary fat tissue does not. To
assess margin status, a glass slide is brought against the
borders of the excised specimen. Next, cells sticking to the
glass surface are ﬁxated, stained, and microscopically
evaluated.
84 Several studies have concluded that IOTPC is
inexpensive, accurate, quick, and saves tissue for perma-
nent sectioning and histopathological examination.
84–86
Klimberg et al. evaluated IOTPC for accuracy in diag-
nosis as well as margin assessment during surgery in a
prospective trial in 428 patients.
84 They reported a diag-
nostic sensitivity and speciﬁcity of 96% and 100%,
respectively, and a margin status sensitivity and speciﬁcity
of both 100%. Weinberg et al. compared the efﬁcacy of
IOTPC to other histopathological assessment techniques,
such as deﬁnitive histopathological assessment and intra-
operative FSA in a database of 1,713 patients.
87 They
reported that intraoperative margin assessment using
IOTPC signiﬁcantly reduced LR rates compared with
conventional methods (2.8% vs. 8.8%; p\0.0001).
Although the overall results seem promising, IOTPC is
not as commonly used as might be expected based on
reported LR rates and detection rates of positive margins.
A possible explanation might be the likelihood of artifacts
caused by draught and surface cautery.
4 Also, IOTPC is
proven less effective in distinguishing lobular carcinoma.
85
Another important shortcoming of IOTPC is that close
margins are not taken into account, because only superﬁcial
tumor cells are detected with the technique. Therefore, no
information is gathered on margin width, multifocality, and
quantity of cancerous cells approaching the cut edge.
STANDARDIZED CAVITY SHAVING
To avoid the earlier-mentioned difﬁculties in intraop-
erative cytological or histological techniques, some authors
have suggested that standardized surgical cavity shaving
could achieve the intended reduction in positive-margin
rates.
88 Hereto, all cut edges are shaved systematically
after excision of the primary tumor to remove any residual
disease.
Huston et al. compared the number of systematically
shaved cavity edges to the achieved deﬁnitive histopathol-
ogical margin status and found an inverted correlation
between the rate of positive margin status and the total
volume of breast tissue removed.
89 Similar results were
found by Janes et al.
90 Because cavity shaving requires
additional tissue resection, cosmetic outcome, and thereby
one of the primary objectives of BCT, is compromised as a
consequence.
89,90 Furthermore, standardized cavity shaving
stilldoesnotprovidecertaintyinachievingnegativemargins
duetothelackofintraoperativeassessmentofmarginstatus.
FUTURE DIRECTIONS
In conclusion, because most of the current techniques
result in a relatively high rate of positive resection margins
together with a clear impact on LR rates and cosmetic
results, new innovative surgical approaches and methods
for intraoperative margin assessment are needed.
6,10 In the
following section, innovative applications of radioguided
surgery and optical imaging are addressed.
Positron Emission Tomography Imaging
18F-ﬂuoro-2-deoxy-D-glucose (
18F-FDG) positron emis-
sion tomography (PET) imaging is considered a powerful
imaging modality for diagnosis, staging, and monitoring of
various malignancies, including breast cancer.
91
The oncologic applications of PET are still expanding
with the development of new positron-emitting radiophar-
maceuticals and imaging techniques.
92 Recently, the
suitability of
18F-FDG as a tracer for tumors has led to an
interest in its use in PET–probe-guided BCT (Fig. 1). The
radiopharmaceutical
18F-FDG demarcates sites of high
glucose metabolic activity, such as tumors, inﬂammation,
and infection.
93 Because breast tumors frequently overex-
press the facilitative glucose transporter GLUT1, uptake of
the glucose analogue
18F-FDG may be increased in breast
cancer cells.
94,95
Hand-held PET-probes have become available, which
allow for the detection of high-energy gamma rays during
surgery and may facilitate localization of breast carcinoma
by offering the surgeon real-time, intraoperative evaluation
of tumor localization and margin status.
96,97 The use of
hand-held probes for the detection of
18F-FDG accumu-
lating tumors has been shown previously for various
malignancies.
91,92,97–99
Sensitivity and speciﬁcity of PET are relatively high for
18F-FDG-avid breast tumors.
100,101 However, because of
limited spatial resolution of PET imaging, small tumors
(\1 cm) are difﬁcult to detect, whereas breast screening
programs and technological developments have led to a
considerable reduction in the size of breast cancers being
detected.
97,102,103 The same limited spatial resolution is of
major concern for the intraoperative detection of positive
margins in itself. Also, PET has a limited role in patients
Surgical Margins in Breast-Conserving Therapy 2723with well-differentiated and lobular types of breast can-
cer.
104 Additionally, PET lacks speciﬁcity, because normal
physiologic uptake of
18F-FDG can be demonstrated to
varying degrees in nonmalignant tissues, such as inﬂam-
matory tissue.
91 Finally, PET has the disadvantage of high
costs and radiation exposure to primary operating person-
nel during the intraoperative
18F-FDG PET procedure is
expected to be relatively high.
101,102
Further development of more speciﬁc radiopharmaceu-
ticals may compensate in part for the current limitations
associated with
18F-FDG PET imaging. In carefully
selected patients, the intraoperative use of a PET-probe
may provide a useful tool to improve surgical outcome.
93
However, its use in BCT warrants further exploration on
feasibility and validation and at this stage cannot be con-
sidered to compete with the current techniques.
91
Radioguided Occult Lesion Localization
Radioguided occult lesion localization (ROLL), intro-
duced by Luini et al. in 1996, is an upcoming surgical
technique and theragnostic tool for intraoperative locali-
zation and simultaneous resection of nonpalpable tumors of
the breast.
105
The technique makes use of a nonspeciﬁc radioisotope,
which is injected into the tumor under stereotactic or
ultrasonographic guidance. The exact position of the pri-
mary tumor can be assessed intraoperatively by use of a
hand-held gamma probe (Fig. 1). After excision of the
primary tumor, the probe also can be used to search for any
residual areas of high radioactivity.
106
The injection of the nonspeciﬁc radioisotope into the
tumor is a fundamental step in the ROLL procedure and
has to be very accurate to minimize false-negative and
false-positive results. Several studies have shown that the
radioisotope was correctly positioned in 95% to 100% of
patients.
3,65,106–110 However, spillage of radiotracer within
the mammary gland during the ROLL procedure might
decrease accuracy of location of the lesion.
111 Furthermore,
the amount of tracer injected needs to correlate with tumor
size.
Alternatively, a radioactive iodine (
125I) seed can be
implanted at the tumor, followed by radioguided localiza-
tion and excision of the tumor together with the radioactive
seed.
112 Hughes et al. analyzed 383 patients treated with
radioguided seed localization (RSL) compared with 99
patients treated with WGL and considered the technique to
be safe, effective, and more patient-friendly compared with
WGL.
113 Additionally, RSL was reported to reduce the
incidence of inadequate surgical margins compared with
WGL (26% vs. 57%, respectively; p = 0.02).
112 However,
although RSL might prove valuable for BCT in the future,
experience with this technique is still limited.
Sarlos et al. analyzed the oncologic safety of the ROLL
procedure and the effectiveness of tumor localization in a
prospective, controlled trial.
110 In 20% of patients with
invasive ductal carcinoma (IDC), the tumor was excised
inadequately (margin B1 mm) at the initial surgical pro-
cedure.
110 These results are consistent with margin
positivity reported by others, ranging from 11% to
17%.
3,65,114 The detection rate of nonpalpable breast
tumors during surgery was found to be 98%.
Although the clinical efﬁcacy of ROLL compared with
WGL was found to be similar in two prospective RCTs,
there were several aspects in which ROLL exceeded the
current standard of WGL.
3,107 Rampaul et al. concluded
that ROLL was less painful for the patient and was an
easier technique to perform surgically.
107 Furthermore, the
ROLL procedure could be combined with lymphatic
mapping and sentinel lymph node biopsy, which makes it
more patient-friendly compared with WGL.
112,115 ROLL
was reported to signiﬁcantly reduce pre- and intraoperative
localization time of nonpalpable breast tumors.
3 However,
the total duration of the surgical procedure was not reduced
by ROLL.
3,65,107,114 Regarding costs, WGL is probably
exceeded by ROLL, although this effect could be leveled
off by the potential net savings that accompany a reduction
of re-excision rates.
3
In conclusion, ROLL seems to be a simple, accurate,
and relatively safe technique compared with the current
standard of WGL.
106–109 Further research is needed to
elucidate the position of ROLL for the treatment of non-
palpable breast tumors. Currently, a large, multicenter,
clinical trial is being conducted in the Netherlands, in
which ROLL is being compared to WGL regarding the
percentage of positive margins, cost-effectiveness, patient
comfort, and cosmetic outcome.
116
Near-Infrared Fluorescence Optical Imaging
In recent years, signiﬁcant progress has been made in
the development of optical imaging systems and ﬂuores-
cent contrast agents for clinical applications.
117–119 Several
animal and clinical studies have shown the potential use of
near-infrared ﬂuorescence (NIRF) optical imaging to
improve the therapeutic outcome of surgery.
120–126
It must be emphasized that NIRF imaging on itself is not
possible without the use of near-infrared (NIR) ﬂuorescent
molecular probes (ﬂuorochromes), for which several groups
can be distinguished. One group consists of ‘‘targeted ﬂu-
orochromes,’’ which are speciﬁc for certain biomarkers
involved in breast cancer, such as vascular endothelial
growth factor (VEGF) receptor, epidermal growth factor
(EGF) receptor, or the Her2/neu receptor.
127–132 Another
group is formed by the ‘‘activatable probes,’’ which show
virtually no ﬂuorescence activity in their native state,
2724 R. G. Pleijhuis et al.thereby minimizing background signals.
119 However,
after activation by a speciﬁc enzyme, the probe emits a
bright ﬂuorescence signal when appropriately excited
(Fig. 2).
119,121,133 A number of enzymes that play a role in
carcinogenesis and tumor spreading can already be visual-
ized with activatable probes, including proteases, such as
cathepsin B, cathepsin D, and matrix metalloproteinase 2
(MMP2).
121,133–137
An optical imaging technique commonly used is two-
dimensional (2D) ﬂuorescence reﬂectance imaging (FRI),
also known as epi-illumination ﬂuorescence imaging. FRI
with a hand-held imaging device could complement BCT
by visualizing tumor delineation, remnant disease, and
pinpointing suspicious lymph nodes, thereby enabling the
surgeon to detect (diagnostic) and excise (therapeutic)
malignant tissue and possible residual disease at the same
time (Figs. 1, 3).
119,121,122,138
The use of NIRF optical imaging offers additional
advantages: the technology is safe, simple to operate,
fast, high resolution (as low as 10 lm), relatively inex-
pensive, and makes use of nonionizing
radiation.
119,122,124,139–141 Besides the aforementioned
advantages, NIRF optical imaging does have limitations,
which originate from the intrinsic characteristics of light
propagation through tissue.
142 Especially, besides
absorption and scattering of light, autoﬂuorescence can
reduce detection sensitivity and imaging performance due
to absorbance and subsequent emission of light by
intrinsic tissue ﬂuorochromes.
143,144 Although the use of
FRI for noninvasive detection of breast cancer is
restricted because of limited depth resolution and a
nonlinear dependence between the signal detected on the
optical properties of tissue and the depth of the activity,
the technique is well suited for intraoperative imaging
applications.
119,121,122,139 Clinical applications for NIRF
optical imaging are expected to expand rapidly, although
further work is needed to overcome the aforementioned
limitations of the technique.
117,145
FIG. 2 Schematic example of the mechanism behind an activatable
probe. The probe is dark in its native state, thereby keeping unwanted
background signals to a minimum (a). After cleavage of the backbone
carrier by a speciﬁc enzyme, the probe will ﬂuoresce when excited
with light of a deﬁned wavelength (b)
FIG. 1 New evolving imaging modalities for intraoperative margin assessment in breast-conserving therapy: (a) radioguided occult lesions
localization (ROLL); (b) positron emission tomography (PET); and (c) near-infrared ﬂuorescence (NIRF) optical imaging
Surgical Margins in Breast-Conserving Therapy 2725CONCLUSIONS
Current imaging techniques used in BCT result in
positive surgical margins in 20% to 40% of patients who
undergo breast-conserving surgery. Risk factors associated
with positive margins are predominantly related to tumor
biology factors or patient characteristics and, therefore,
cannot be inﬂuenced directly to improve surgical outcome.
Instead, multidisciplinary research should focus on tech-
niques that provide the surgeon with a so-called
‘‘theragnostic’’ tool, enabling the surgeon to obtain an
optimal balance between safe surgical margins and good
cosmetic results. Current techniques present signiﬁcant
difﬁculties in this perspective. New innovative techniques,
such as radioguided and NIRF optical imaging-guided
surgery, are emerging. Further studies are being performed
to elucidate their potential value in improving surgical
outcome and reducing the need for re-excision in BCT.
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